Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis

1. Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne M, et al. Global incidence and trends in intra- and extrahepatic cholangiocarcinoma from 1993 to 2012. Cancer 2020; 126: 2666–78. doi: 10.1002/cncr.32803 FlorioAA FerlayJ ZnaorA RuggieriD AlvarezCS LaversanneM Global incidence and trends in intra- and extrahepatic cholangiocarcinoma from 1993 to 2012 Cancer 2020 126 2666 78 10.1002/cncr.32803 Open DOISearch in Google Scholar

2. Kim D, Konyn P, Cholankeril G, Bonham CA, Ahmed A. Trends in the mortality of biliary tract cancers based on their anatomical site in the United States from 2009 to 2018. Am J Gastroenterol 2021; 116: 1053–62. doi: 10.14309/ajg.0000000000001151 KimD KonynP CholankerilG BonhamCA AhmedA Trends in the mortality of biliary tract cancers based on their anatomical site in the United States from 2009 to 2018 Am J Gastroenterol 2021 116 1053 62 10.14309/ajg.0000000000001151 Open DOISearch in Google Scholar

3. Rahman R, Ludvigsson JF, von Seth E, Lagergren J, Bergquist A, Radkiewicz C. Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study. Eur J Cancer 2022; 175: 291–8. doi: 10.1016/j.ejca.2022.08.032 RahmanR LudvigssonJF von SethE LagergrenJ BergquistA RadkiewiczC Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study Eur J Cancer 2022 175 291 8 10.1016/j.ejca.2022.08.032 Open DOISearch in Google Scholar

4. Wu L, Tsilimigras DI, Paredes AZ, Mehta R, Hyer JM, Merath K, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: Facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg 2019; 43: 1777–87. doi: 10.1007/s00268-019-04966-4 WuL TsilimigrasDI ParedesAZ MehtaR HyerJM MerathK Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: Facility type is associated with margin status, use of lymphadenectomy and overall survival World J Surg 2019 43 1777 87 10.1007/s00268-019-04966-4 Open DOISearch in Google Scholar

5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273–81. doi: 10.1056/NEJMoa0908721 ValleJ WasanH PalmerDH CunninghamD AnthoneyA MaraveyasA Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 2010 362 1273 81 10.1056/NEJMoa0908721 Open DOISearch in Google Scholar

6. Oh DY, Ruth HA, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVIDoa2200015. doi: 10.1056/EVIDoa2200015 OhDY RuthHA QinS ChenLT OkusakaT VogelA Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer NEJM Evid 2022 1 EVIDoa2200015 10.1056/EVIDoa2200015 Open DOISearch in Google Scholar

7. Kim GH, Kim PH, Kim JH, Kim PN, Won HJ, Shin YM, et al. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Eur Radiol 2022; 32: 1205–15. doi: 10.1007/s00330-021-08216-x KimGH KimPH KimJH KimPN WonHJ ShinYM Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis Eur Radiol 2022 32 1205 15 10.1007/s00330-021-08216-x Open DOISearch in Google Scholar

8. Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6: 2–6. doi: 10.21037/hbsn.2016.09.07 ShindohJ Ablative therapies for intrahepatic cholangiocarcinoma Hepatobiliary Surg Nutr 2017 6 2 6 10.21037/hbsn.2016.09.07 Open DOISearch in Google Scholar

9. Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A Phase 2 clinical trial. JAMA Oncol 2020; 6: 60–7. doi: 10.1001/jamaoncol.2019.3718 CercekA BoernerT TanBR ChouJF GönenM BoucherTM Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A Phase 2 clinical trial JAMA Oncol 2020 6 60 7 10.1001/jamaoncol.2019.3718 Open DOISearch in Google Scholar

10. Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A Phase 2 clinical trial. JAMA Oncol 2020; 6: 51–9. doi: 10.1001/jamaoncol.2019.3702 EdelineJ TouchefeuY GuiuB FargeO TougeronD BaumgaertnerI Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A Phase 2 clinical trial JAMA Oncol 2020 6 51 9 10.1001/jamaoncol.2019.3702 Open DOISearch in Google Scholar

11. Zhou TY, Zhou GH, Zhang YL, Nie CH, Zhu TY, Wang HL, et al. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer 2020; 11: 4534–41. doi: 10.7150/jca.39410 ZhouTY ZhouGH ZhangYL NieCH ZhuTY WangHL Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma J Cancer 2020 11 4534 41 10.7150/jca.39410 Open DOISearch in Google Scholar

12. Wright GP, Perkins S, Jones H, Zureikat AH, Marsh JW, Holtzman MP, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: A comparison of surgical resection with intra-arterial therapies. Ann Surg Oncol 2018; 25: 83–90. doi: 10.1245/s10434-017-6110-1 WrightGP PerkinsS JonesH ZureikatAH MarshJW HoltzmanMP Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: A comparison of surgical resection with intra-arterial therapies Ann Surg Oncol 2018 25 83 90 10.1245/s10434-017-6110-1 Open DOISearch in Google Scholar

13. Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging 2018; 45: 1731–41. doi: 10.1007/s00259-018-3990-7 ManceauV PalardX RollandY PrachtM Le SourdS LaffontS A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy Eur J Nucl Med Mol Imaging 2018 45 1731 41 10.1007/s00259-018-3990-7 Open DOISearch in Google Scholar

14. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-institutional Phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016; 34: 460–8. doi: 10.1200/JCO.2015.64.2710 HongTS WoJY YeapBY Ben-JosefE McDonnellEI BlaszkowskyLS Multi-institutional Phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma J Clin Oncol 2016 34 460 8 10.1200/JCO.2015.64.2710 Open DOISearch in Google Scholar

15. Smart AC, Goyal L, Horick N, Petkovska N, Zhu AX, Ferrone CR, et al. Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020; 27: 1122–9. doi: 10.1245/s10434-019-08142-9 SmartAC GoyalL HorickN PetkovskaN ZhuAX FerroneCR Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma Ann Surg Oncol 2020 27 1122 9 10.1245/s10434-019-08142-9 Open DOISearch in Google Scholar

16. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis. J Clin Oncol 2016; 34: 219–26. doi: 10.1200/JCO.2015.61.3778 TaoR KrishnanS BhosalePR JavleMM AloiaTA ShroffRT Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis J Clin Oncol 2016 34 219 26 10.1200/JCO.2015.61.3778 Open DOISearch in Google Scholar

17. Smart AC, Goyal L, Horick N, Petkovska N, Zhu AX, Ferrone CR, et al. Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020; 27: 1122–9. doi: 10.1245/s10434-019-08142-9 SmartAC GoyalL HorickN PetkovskaN ZhuAX FerroneCR Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma Ann Surg Oncol 2020 27 1122 9 10.1245/s10434-019-08142-9 Open DOISearch in Google Scholar

18. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLOS Med 2009; 6: e1000097. doi: 10.1371/journal.pmed.1000097 MoherD LiberatiA TetzlaffJ AltmanDG GroupTP Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement PLOS Med 2009 6 e1000097 10.1371/journal.pmed.1000097 Open DOISearch in Google Scholar

19. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. University of Ottawa, 2222. [cited 2022 Nov 17]. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp WellsG SheaB O’ConnellD PetersonJ WelchV LososM The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses University of Ottawa 2222. [cited 2022 Nov 17]. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Search in Google Scholar

20. Yang XG, Sun YY, Li DS, Xu GH, Huang XQ. Efficacy and safety of drug-eluting beads transarterial chemoembolization combining immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: A propensity score matching analysis. Front Immunol 2022; 13: 940009. doi: 10.3389/fimmu.2022.940009 YangXG SunYY LiDS XuGH HuangXQ Efficacy and safety of drug-eluting beads transarterial chemoembolization combining immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: A propensity score matching analysis Front Immunol 2022 13 940009 10.3389/fimmu.2022.940009 Open DOISearch in Google Scholar

21. Yan X, Zhuang LP, Ning ZY, Wang P, Meng ZQ. Addition of thermal ablation to systemic chemotherapy for the treatment of unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis. Expert Rev Gastroenterol Hepatol 2022; 16: 81–8. doi: 10.1080/17474124.2022.2021067 YanX ZhuangLP NingZY WangP MengZQ Addition of thermal ablation to systemic chemotherapy for the treatment of unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis Expert Rev Gastroenterol Hepatol 2022 16 81 8 10.1080/17474124.2022.2021067 Open DOISearch in Google Scholar

22. Sun X, Li C, Huang M, Zhao Y. Efficacy of transcatheter arterial chemoinfusion combined with Gemcitabine + S-1 systemic chemotherapy in treating advanced intrahepatic cholangiocarcinoma. Minerva Med 2021 Feb 1. [Ahead of print]. doi: 10.23736/S0026-4806.20.07249-3 SunX LiC HuangM ZhaoY Efficacy of transcatheter arterial chemoinfusion combined with Gemcitabine + S-1 systemic chemotherapy in treating advanced intrahepatic cholangiocarcinoma Minerva Med 2021 Feb 1 [Ahead of print]. 10.23736/S0026-4806.20.07249-3 Open DOISearch in Google Scholar

23. Gairing SJ, Thol F, Müller L, Hahn F, Thomaidis T, Czauderna C, et al. The addition of transarterial chemoembolization to palliative chemotherapy extends survival in intrahepatic cholangiocarcinoma. J Clin Med 2021; 10: 2732. doi: 10.3390/jcm10122732 GairingSJ TholF MüllerL HahnF ThomaidisT CzaudernaC The addition of transarterial chemoembolization to palliative chemotherapy extends survival in intrahepatic cholangiocarcinoma J Clin Med 2021 10 2732 10.3390/jcm10122732 Open DOISearch in Google Scholar

24. Hu Y, Hao M, Chen Q, Chen Z, Lin H. Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma. Am J Transl Res 2020; 12: 6584–98. PMID: 33194055 HuY HaoM ChenQ ChenZ LinH Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma Am J Transl Res 2020 12 6584 98 33194055 Search in Google Scholar

25. Verma V, Appiah AK, Lautenschlaeger T, Adeberg S, Simone CB, Lin C. Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base. J Gastrointest Oncol 2018; 9: 527–35. doi: 10.21037/jgo.2018.01.15 VermaV AppiahAK LautenschlaegerT AdebergS SimoneCB LinC Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base J Gastrointest Oncol 2018 9 527 35 10.21037/jgo.2018.01.15 Open DOISearch in Google Scholar

26. Chang WW, Hsiao PK, Qin L, Chang CL, Chow JM, Wu SY. Treatment outcomes for unresectable intrahepatic cholangiocarcinoma: Nationwide, population-based, cohort study based on propensity score matching with the Mahalanobis metric. Radiother Oncol 2018; 129: 284–92. doi: 10.1016/j.radonc.2018.09.010 ChangWW HsiaoPK QinL ChangCL ChowJM WuSY Treatment outcomes for unresectable intrahepatic cholangiocarcinoma: Nationwide, population-based, cohort study based on propensity score matching with the Mahalanobis metric Radiother Oncol 2018 129 284 92 10.1016/j.radonc.2018.09.010 Open DOISearch in Google Scholar

27. Konstantinidis IT, Koerkamp BG, Do RKG, Gönen M, Fong Y, Allen PJ, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016; 122: 758–65. doi: 10.1002/cncr.29824 KonstantinidisIT KoerkampBG DoRKG GönenM FongY AllenPJ Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone Cancer 2016 122 758 65 10.1002/cncr.29824 Open DOISearch in Google Scholar

28. Edeline J, Du FL, Rayar M, Rolland Y, Beuzit L, Boudjema K, et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med 2015; 40: 851–5. doi: 10.1097/RLU.0000000000000904 EdelineJ DuFL RayarM RollandY BeuzitL BoudjemaK Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma Clin Nucl Med 2015 40 851 5 10.1097/RLU.0000000000000904 Open DOISearch in Google Scholar

29. Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 2013; 8: 292. doi: 10.1186/1748-717X-8-292 KimYI ParkJW KimBH WooSM KimTH KohYH Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma Radiat Oncol 2013 8 292 10.1186/1748-717X-8-292 Open DOISearch in Google Scholar

30. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16. doi: 10.1186/1745-6215-8-16 TierneyJF StewartLA GhersiD BurdettS SydesMR Practical methods for incorporating summary time-to-event data into meta-analysis Trials 2007 8 16 10.1186/1745-6215-8-16 Open DOISearch in Google Scholar

31. National Comprehensive Cancer Network^®. Hepatobiliary Cancers, version 4.2022, NCCN clinical practice guidelines in oncology. [Internet] 2022. [cited 2022 Dec 20]. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1438/ National Comprehensive Cancer Network® Hepatobiliary Cancers, version 4.2022, NCCN clinical practice guidelines in oncology. [Internet] 2022 [cited 2022 Dec 20]. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1438/ Search in Google Scholar

32. Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, et al. Advanced intrahepatic cholangiocarcinoma: Post hoc analysis of the ABC-01, -02, and -03 clinical trials. JNCI-J Natl Cancer Inst 2020; 112: 200–10. doi: 10.1093/jnci/djz071 LamarcaA RossP WasanHS HubnerRA McNamaraMG LopesA Advanced intrahepatic cholangiocarcinoma: Post hoc analysis of the ABC-01, -02, and -03 clinical trials JNCI-J Natl Cancer Inst 2020 112 200 10 10.1093/jnci/djz071 Open DOISearch in Google Scholar

33. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 796–807. doi: 10.1016/S1470-2045(20)30157-1 Abou-AlfaGK MacarullaT JavleMM KelleyRK LubnerSJ AdevaJ Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 2020 21 796 807 10.1016/S1470-2045(20)30157-1 Open DOISearch in Google Scholar

34. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007; 37: 843–51. doi: 10.1093/jjco/hym116 YonemotoN FuruseJ OkusakaT YamaoK FunakoshiA OhkawaS A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer Jpn J Clin Oncol 2007 37 843 51 10.1093/jjco/hym116 Open DOISearch in Google Scholar

35. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16: 279–81. doi: 10.1093/annonc/mdi046 ThongprasertS NapapanS CharoentumC MoonprakanS Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma Ann Oncol 2005 16 279 81 10.1093/annonc/mdi046 Open DOISearch in Google Scholar

36. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95: 848–52. doi: 10.1038/sj.bjc.6603334 HarderJ RieckenB KummerO LohrmannC OttoF UsadelH Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer Br J Cancer 2006 95 848 52 10.1038/sj.bjc.6603334 Open DOISearch in Google Scholar

37. Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: A Phase 2 clinical trial. JAMA Oncol 2018; 4: 1707–12. doi: 10.1001/jamaoncol.2018.3277 SahaiV CatalanoPJ ZalupskiMM LubnerSJ MengeMR NimeiriHS Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: A Phase 2 clinical trial JAMA Oncol 2018 4 1707 12 10.1001/jamaoncol.2018.3277 Open DOISearch in Google Scholar

38. Borbath I, Ceratti A, Verslype C, Demols A, Delaunoit T, Laurent S, et al. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology. Ann Oncol 2013; 24: 2824–9. doi: 10.1093/annonc/mdt337 BorbathI CerattiA VerslypeC DemolsA DelaunoitT LaurentS Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology Ann Oncol 2013 24 2824 9 10.1093/annonc/mdt337 Open DOISearch in Google Scholar

39. Nehls O, Oettle H, Hartmann JT, Hofheinz R-D, Hass HG, Horger MS, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98: 309–15. doi: 10.1038/sj.bjc.6604178 NehlsO OettleH HartmannJT HofheinzR-D HassHG HorgerMS Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial Br J Cancer 2008 98 309 15 10.1038/sj.bjc.6604178 Open DOISearch in Google Scholar

40. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis. J Clin Oncol 2016; 34: 219–26. doi: 10.1200/JCO.2015.61.3778 TaoR KrishnanS BhosalePR JavleMM AloiaTA ShroffRT Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis J Clin Oncol 2016 34 219 26 10.1200/JCO.2015.61.3778 Open DOISearch in Google Scholar

41. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013; 31: 3219–25. doi: 10.1200/JCO.2013.48.8585 LiJ QinS XuJ GuoW XiongJ BaiY Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial J Clin Oncol 2013 31 3219 25 10.1200/JCO.2013.48.8585 Open DOISearch in Google Scholar

42. Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2021; 6: 559–68. doi: 10.1016/S2468-1253(21)00109-6 QinS LiQ GuS ChenX LinL WangZ Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Lancet Gastroenterol Hepatol 2021 6 559 68 10.1016/S2468-1253(21)00109-6 Open DOISearch in Google Scholar

43. Li F, Zhu T, Cao B, Wang J, Liang L. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer 2017; 84: 184–92. doi: 10.1016/j.ejca.2017.07.037 LiF ZhuT CaoB WangJ LiangL Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance Eur J Cancer 2017 84 184 92 10.1016/j.ejca.2017.07.037 Open DOISearch in Google Scholar

44. Lin Y, Wu Z, Zhang J, Hu X, Wang Z, Wang B, et al. Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment. Tumour Biol 2017; 39: 1010428317711033. doi: 10.1177/1010428317711033 LinY WuZ ZhangJ HuX WangZ WangB Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment Tumour Biol 2017 39 1010428317711033 10.1177/1010428317711033 Open DOISearch in Google Scholar

45. Nie C, Lv H, Xing Y, Chen B, Xu W, Wang J, et al. The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study. BMC Cancer 2021; 21: 189. doi: 10.1186/s12885-021-07907-4 NieC LvH XingY ChenB XuW WangJ The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study BMC Cancer 2021 21 189 10.1186/s12885-021-07907-4 Open DOISearch in Google Scholar

46. Wang D, Yang X, Long J, Lin J, Mao J, Xie F, et al. The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: A prospective clinical study. Front Oncol 2021; 11: 646979. doi: 10.3389/fonc.2021.646979 WangD YangX LongJ LinJ MaoJ XieF The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: A prospective clinical study Front Oncol 2021 11 646979 10.3389/fonc.2021.646979 Open DOISearch in Google Scholar

47. Hai-Tao Zhao. A study of second-line treatment with apatinib in patients with advanced intrahepatic cholangiocarcinoma. 2023. [cited 2023 Sep 10]. Available at: https://clinicaltrials.gov/study/NCT03251443 ZhaoHai-Tao A study of second-line treatment with apatinib in patients with advanced intrahepatic cholangiocarcinoma 2023 [cited 2023 Sep 10]. Available at: https://clinicaltrials.gov/study/NCT03251443 Search in Google Scholar